This is a summary of the European public assessment report (EPAR) for Eklira Genuair. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Eklira Genuair.
For practical information about using Eklira Genuair, patients should read the package leaflet or contact their doctor or pharmacist.
Eklira Genuair : EPAR - Summary for the public (PDF/95.32 KB)
First published: 19/09/2012
Last updated: 19/06/2017
Eklira Genuair : EPAR - Risk-management-plan summary (PDF/416.5 KB)
First published: 01/12/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Pulmonary Disease, Chronic Obstructive
|Anatomical therapeutic chemical (ATC) code||
Covis Pharma Europe B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
Gustav Mahlerplein 2
09/01/2023 Eklira Genuair - EMEA/H/C/002211 - N/0051
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Drugs for obstructive airway diseases
Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).